
Overview
Background
Associate Professor Joy Wolfram leads an extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of medicines directly to the clinic to alter the trajectory of life-threatening diseases, improve patient outcomes, and prolong healthy lifespans. Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, Australia (#41 in Best Global Universities, U.S. News & World Report).
MISSION
1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer
2) Save lives by manufacturing at scale, by delivering national manufacturing innovation and a skilled workforce
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine
Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional pharmaceuticals due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading of extracellular vesicles to develop therapeutics.
FOCUS AREAS
1) Developing improved methods for extracellular vesicle isolation from human biofluids
2) Designing hybrid drug delivery systems with extracellular vesicle and synthetic components for a ‘best-of-both-worlds’ approach to treat cardiovascular disease and aging kidney disease
3) Understanding the role of extracellular vesicles in cancer immunoevasion and metastasis
The research program has resulted in more than 100 publications in journals, such as, Nature Nanotechnology, Materials Today, and Nature Reviews Materials. These publications have been cited 16,800 times (Google Scholar). The Wolfram Laboratory has collaborated with 160 universities and industry partners across 45 countries (Scopus). The research program has also been featured in more than 100 presentations at scientific meetings, including 80+ invited talks and nine international keynote talks.
Wolfram is actively involved in community outreach and education, including in her previous roles as the Chair of an education and outreach working group of the National Institutes of Health in the United States and the Associate Program Director of the PhD Program in Regenerative Sciences at Mayo Clinic (Best Hospital in the World, Newsweek). As a TED speaker, she strives to bring science to a wide audience.
She has received 40+ awards from nine countries, including the 2016 Amgen Scholars Ten to Watch List (best and brightest up-and-comers in science and medicine across 42 countries), the 2019 Forbes 30 under 30 list in Health Care in the United States/Canada, the 2019 shortlist for the Nature Research Award for Inspiring Science (one of ten worldwide), and the 2021 Finnish Expatriate of the Year (past recipients include Nobel Memorial Prize winners, Millennium Technology Prize winners, and Formula 1 drivers). She is in the top 1% of researchers worldwide in the categories of ‘Biology & Biochemistry’ and ‘Pharmacology & Toxicology' (Essential Science Indicators, 2023) and in the top 0.5% in 'Extracellular Vesicles' (ScholarGPS 5/2024).
Availability
- Associate Professor Joy Wolfram is:
- Available for supervision
- Media expert
Qualifications
- Bachelor, University of Helsinki*
- Masters (Coursework), University of Helsinki*
- Doctor of Philosophy, University of the Chinese Academy of Science
- Member, Global Young Academy, Global Young Academy
- Honorary Academic, Houston Methodist Hospital, Houston Methodist Hospital
- Member, The Swedish Academy of Engineering Sciences in Finland, The Swedish Academy of Engineering Sciences in Finland
Works
Search Professor Joy Wolfram’s works on UQ eSpace
2014
Journal Article
Safety of nanoparticles in medicine
Wolfram, Joy, Zhu, Motao, Yang, Yong, Shen, Jianliang, Gentile, Emanuela, Paolino, Donatella, Fresta, Massimo, Nie, Guangjun, Chen, Chunying, Shen, Haifa, Ferrari, Mauro and Zhao, Yuliang (2014). Safety of nanoparticles in medicine. Current Drug Targets, 15 (10) A001.
2014
Journal Article
Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics
Shen, Jianliang, Kim, Han-Cheon, Su, Hua, Wang, Feng, Wolfram, Joy, Kirui, Dickson, Mai, Junhua, Mu, Chaofeng, Ji, Liang-Nian, Mao, Zong-Wan and Shen, Haifa (2014). Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics. Theranostics, 4 (5), 487-497. doi: 10.7150/thno.8263
2014
Journal Article
Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes
Paolino, Donatella, Cosco, Donato, Gaspari, Marco, Celano, Marilena, Wolfram, Joy, Voce, Pasquale, Puxeddu, Efisio, Filetti, Sebastiano, Celia, Christian, Ferrari, Mauro, Russo, Diego and Fresta, Massimo (2014). Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes. Biomaterials, 35 (25), 7101-7109. doi: 10.1016/j.biomaterials.2014.04.088
2014
Journal Article
Mechanistic features of nanodiamonds in the lapping of magnetic heads
Jiang, Xionghua, Chen, Zhenxing, Wolfram, Joy and Yang, Zhizhou (2014). Mechanistic features of nanodiamonds in the lapping of magnetic heads. Scientific World Journal, 2014 326427. doi: 10.1155/2014/326427
2014
Journal Article
Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells
Wolfram, Joy, Suri, Krishna, Huang, Yi, Molinaro, Roberto, Borsoi, Carlotta, Scott, Bronwyn, Boom, Kathryn, Paolino, Donatella, Fresta, Massimo, Wang, Jianghua, Ferrari, Mauro, Celia, Christian and Shen, Haifa (2014). Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. Journal of Microencapsulation, 31 (5), 501-507. doi: 10.3109/02652048.2013.879932
2013
Journal Article
Live-cell single-molecule imaging reveals clathrin and caveolin-1 dependent docking of SMAD4 at the cell membrane
Yang, Yong, Wolfram, Joy, Shen, Jianliang, Zhao, Yuliang, Fang, Xiaohong, Shen, Haifa and Ferrari, Mauro (2013). Live-cell single-molecule imaging reveals clathrin and caveolin-1 dependent docking of SMAD4 at the cell membrane. FEBS Letters, 587 (24), 3912-3920. doi: 10.1016/j.febslet.2013.10.041
2013
Journal Article
Liposomal chemotherapeutics
Gentile, Emanuela, Cilurzo, Felisa, Di Marzio, Luisa, Carafa, Maria, Ventura, Cinzia Anna, Wolfram, Joy, Paolino, Donatella and Celia, Christian (2013). Liposomal chemotherapeutics. Future Oncology, 9 (12), 1849-1859. doi: 10.2217/FON.13.146
2013
Journal Article
Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells
Celia, Christian, Trapasso, Elena, Locatelli, Marcello, Navarra, Michele, Ventura, Cinzia Anna, Wolfram, Joy, Carafa, Maria, Morittu, Valeria Maria, Britti, Domenico, Di Marzio, Luisa and Paolino, Donatella (2013). Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells. Colloids and Surfaces B: Biointerfaces, 112, 548-553. doi: 10.1016/j.colsurfb.2013.09.017
2013
Journal Article
High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics
Shen, Jianliang, Xu, Rong, Mai, Junhua, Kim, Han-Cheon, Guo, Xiaojing, Qin, Guoting, Yang, Yong, Wolfram, Joy, Mu, Chaofeng, Xia, Xiaojun, Gu, Jianhua, Liu, Xuewu, Mao, Zong-Wan, Ferrari, Mauro and Shen, Haifa (2013). High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano, 7 (11), 9867-9880. doi: 10.1021/nn4035316
2013
Conference Publication
Joint collaboration between the National Center for Nanoscience and Technology (NCNST) and the Houston Methodist Hospital
Wolfram, Joy, Ferrari, Mauro and Zhao, Yuliang (2013). Joint collaboration between the National Center for Nanoscience and Technology (NCNST) and the Houston Methodist Hospital. ChinaNano2013: International Conference on Nanoscience and Technology, Beijing, China , September 2013.
2013
Conference Publication
Polyarginine induces an antitumor immune response through binding to toll-like receptor 4 (TLR4)
Yang, Yong, Wolfram, Joy, Shen, Haifa, Fang, X. and Ferrari, Mauro (2013). Polyarginine induces an antitumor immune response through binding to toll-like receptor 4 (TLR4). ChinaNano2013: International Conference on Nanoscience and Technology, Beijing, China, September 2013.
2013
Journal Article
Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells
Yang, Yong, Wolfram, Joy, Boom, Kathryn, Fang, Xiaohong, Shen, Haifa and Ferrari, Mauro (2013). Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochemistry and Function, 31 (5), 374-379. doi: 10.1002/cbf.2905
2013
Journal Article
Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors
Molinaro, Roberto, Wolfram, Joy, Federico, Cinzia, Cilurzo, Felisa, Di Marzio, Luisa, Ventura, Cinzia A., Carafa, Maria, Celia, Christian and Fresta, Massimo (2013). Polyethylenimine and chitosan carriers for the delivery of RNA interference effectors. Expert Opinion on Drug Delivery, 10 (12), 1653-1668. doi: 10.1517/17425247.2013.840286
2012
Journal Article
Hesperetin: An inhibitor of the transforming growth factor-β (TGF-β) signaling pathway
Yang, Yong, Wolfram, Joy, Shen, Haifa, Fang, Xiaohong and Ferrari, Mauro (2012). Hesperetin: An inhibitor of the transforming growth factor-β (TGF-β) signaling pathway. European Journal of Medicinal Chemistry, 58, 390-395. doi: 10.1016/j.ejmech.2012.10.028
2012
Conference Publication
Toward understanding and overcoming multiscale mass transport differentials in cancer
Koay, Eugene, Kirui, Dickson, Yang, Yubo, Wolfram, Joy, Shen, Haifa and Ferrari, Mauro (2012). Toward understanding and overcoming multiscale mass transport differentials in cancer. Third Annual Physical Sciences – Oncology Centers (PS-OCs) Investigators Meeting, Tampa, FL United States , April 2012.
2009
Conference Publication
Angiomotin-like protein 2 (AmotL2), a potential target for cancer therapy
Wolfram, Joy, Mojallal, M., Zheng, Y. and Holmgren, L. (2009). Angiomotin-like protein 2 (AmotL2), a potential target for cancer therapy. Amgen Scholars Symposium, Cambridge, United Kingdom, September 2009.
Funding
Current funding
Past funding
Supervision
Availability
- Associate Professor Joy Wolfram is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Developing extracellular vesicle therapeutics for cardiovascular inflammation
Every 12 minutes, one Australian dies of cardiovascular disease, accounting for 40,000+ annual deaths at a cost of $11.8B/year. Want to help us develop treatments for cardiovascular disease, the leading cause of death worldwide?
Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for inflammatory cardiovascular disease.
Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of cardiovascular disease, improve patient outcomes, and prolong healthy lifespan.
This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat cardiovascular disease.
LONG-TERM GOALS
1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat cardiovascular inflammation.
2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.
-
Developing extracellular vesicle therapeutics for aging kidney disease
In the upcoming decades, health care systems are predicted to collapse due to aging-associated diseases. Chronickidney disease is on the rise in the aging population and currently affects an estimated 1.7M Australians at a cost of $1.9B annually.
Want to help us develop treatments for aging kidney disease? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for aging kidney disease.
Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of aging diabetic kidney disease, improve patient outcomes, and prolong healthy lifespan.
This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat aging kidney disease.
LONG-TERM GOALS
1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat aging kidney disease.
2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.
-
Understanding the contribution of extracellular vesicles in breast cancer immunoevasion
The deadliest breast cancer is the triple-negative subtype, which has few treatment options. New treatments are urgently needed to prevent deaths and improve the quality of life for the 3,000 Australians who are diagnosed with triple-negative breast cancer every year.
Want to help us develop treatments for deadly breast cancer? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle-informed understanding and therapeutics for breast cancer.
The immune system is known to play a critical role in detecting and eliminating breast cancer cells and the Wolfram Laboratory has shown that triple-negative breast cancer cells release extracellular vesicles with harmful biomolecules that help the cancer cells avoid detection and destruction by the immune system. The project involves assessing how these extracellular vesicles affect the ability of immune cells to destroy breast cancer cells. The project also involves the development of new treatment options for breast cancer, including engineering natural killer cells to be resistant to extracellular vesicle-mediated suppression.
The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and targeting of extracellular vesicles to alter the trajectory of breast cancer, improve patient outcomes, and prolong healthy lifespan.
LONG-TERM GOALS
1) Uncover the mechanisms by which breast cancer extracellular vesicles suppress the immune system.
2) Develop a new paradigm of therapeutics (using engineered immune cells) to treat triple negative breast cancer.
3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.
Supervision history
Current supervision
-
Doctor Philosophy
Mutation Targeting Therapy for Cancer with dCas9
Principal Advisor
-
Doctor Philosophy
Engineered Extracellular Vesicles for Synergistic Myocardial Infarction Therapy
Principal Advisor
-
Doctor Philosophy
Maximising the success of cancer immunotherapy by preventing extracellular vesicle hijacking of the immune system
Principal Advisor
Other advisors: Dr Allie Lam, Dr Zhengni Liu
-
Doctor Philosophy
The extracellular vesicle bio-nano interactome in cancer metastasis.
Principal Advisor
-
Doctor Philosophy
Extracellular vesicle-based senotherapeutics for aging diabetic kidney disease
Principal Advisor
Other advisors: Dr Zhengni Liu
Media
Enquiries
Contact Associate Professor Joy Wolfram directly for media enquiries about:
- Biomanufacturing
- Bioseparation
- Biotherapeutics
- Breast cancer
- Exosomes
- Extracellular vesicles
- Nanomedicine
- Nanoparticles
- Regenerative medicine
- Scientific outreach
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: